🧪

Hyperlipidemia Hub

Hyperlipidemia is the most modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). This module covers lipid panel interpretation, ASCVD risk stratification, statin therapy concepts, statin intolerance management, and patient education on cholesterol and heart disease prevention.

Cardiology APPsPA/NP StudentsNursesMAsMedical StudentsClinic Staff

← Home

🧪Hyperlipidemia

0/7

📋

Pre-Test — Hyperlipidemia

~2 min

Answer a few quick questions before starting to measure your learning gain.

Overview

Learning Objectives

1.Interpret a basic lipid panel: LDL-C, non-HDL-C, HDL-C, triglycerides
2.Understand the roles of Lp(a) and ApoB in cardiovascular risk
3.Apply ASCVD risk stratification to guide therapy
4.Explain statin therapy concepts, benefits, and common concerns to patients
5.Recognize statin intolerance and know alternative options
6.Educate patients on lifestyle and diet for cholesterol management
7.Communicate with Spanish-speaking patients about cholesterol and medications

Choose Your View

Same topic, different depth. Jump to the view that matches your role.

🩺APP / NP / PA

Pathophysiology, differential, GDMT, and disposition decisions.

Scope: Clinical reasoning, diagnostics, and management. Not procedural or raw-imaging training.

💉Nurse

Triage, escalation criteria, and patient education reinforcement.

Scope: Triage and workflow support. Does not replace institutional protocols or provider direction.

🏥MA / Nurse Tech

Rooming, vitals, red flags, and what to report immediately.

Scope: Safe data collection and escalation. Not independent triage or clinical decision-making.

🎓Student

Start with the lesson and cheat sheet, then test yourself with the quiz.

Scope: Introductory learning, to be used under supervision.

📄Patient Education 🗣️Spanish / Communication 🩺Sim Case 🧠Quiz

APP Lesson: Hyperlipidemia Foundations

Audience: New cardiology APPs, PA/NP students, and clinicians new to cardiology.

Why Lipids Matter in Cardiology

›Atherosclerotic cardiovascular disease (ASCVD) — including myocardial infarction, stroke, and peripheral arterial disease — is the leading cause of death worldwide. Elevated LDL-C is causally linked to ASCVD through decades of epidemiological, genetic, and trial evidence. Lowering LDL-C reduces events proportionally across a wide range of baseline risk.
›In a cardiology clinic, nearly every patient you encounter will have a lipid history. Understanding the lipid panel, risk stratification, and treatment options will help you counsel patients, explain their care, and support the clinical decision-making of your team.

Lipid Panel Components

›LDL-C (Low-Density Lipoprotein Cholesterol): The primary target of lipid-lowering therapy. Often calculated using the Friedewald equation, though direct measurement or the Martin-Hopkins equation is preferred when triglycerides are elevated or LDL is very low.
›Non-HDL-C: Total cholesterol minus HDL-C. Captures all atherogenic lipoproteins including LDL, VLDL, IDL, and Lp(a). Often a better predictor of risk than LDL-C alone, especially when triglycerides are elevated.
›HDL-C (High-Density Lipoprotein Cholesterol): Higher is generally better. HDL <40 mg/dL in men or <50 mg/dL in women is a risk factor. However, pharmacologically raising HDL has not consistently reduced ASCVD events — lifestyle changes are the most effective approach.
›Triglycerides: Elevated TG (>150 mg/dL) is a risk marker. Very high TG (>500 mg/dL) raises risk of pancreatitis and requires specific attention. Often secondary to diet, alcohol, uncontrolled DM, or hypothyroidism.
›Apolipoprotein B (ApoB): Reflects the total number of atherogenic particles. One ApoB per LDL, IDL, and VLDL particle. Increasingly recognized as a superior predictor of residual risk compared to LDL-C alone.
›Lipoprotein(a) — Lp(a): A genetically determined, largely treatment-resistant lipoprotein that independently increases ASCVD and aortic valve disease risk. Should be measured at least once in adults to identify high-risk individuals. Emerging therapies (RNA-targeted agents) are in late-stage trials.

ASCVD Risk Stratification (2026 ACC/AHA)

›The 2026 ACC/AHA dyslipidemia guideline replaces the Pooled Cohort Equations with the AHA PREVENT equations, which estimate 10- and 30-year ASCVD risk in adults aged 30–79. PREVENT incorporates kidney function and metabolic factors and runs roughly 40–50% lower than the old PCE for the same patient, so the risk-category cutoffs are correspondingly lower.
›PREVENT 10-year risk categories: Low (<3%), Borderline (3 to <5%), Intermediate (5 to <10%), High (≥10%). Established ASCVD is handled under secondary prevention; "very high risk" ASCVD = a major event plus multiple high-risk conditions.
›A defining 2026 change: the guideline restores explicit LDL-C treatment goals (the 2018 guideline had moved away from numeric goals). Primary-prevention goals — borderline/intermediate risk: LDL-C <100 mg/dL; high risk: <70 mg/dL. Secondary prevention — clinical ASCVD: <70 mg/dL; ASCVD at very high risk: <55 mg/dL (and non-HDL-C <85 mg/dL).
›Risk-enhancing factors still tip borderline/intermediate patients toward therapy: family history of premature ASCVD, LDL ≥160 mg/dL, chronic kidney disease, metabolic syndrome, inflammatory conditions (RA, psoriasis, HIV), elevated Lp(a), elevated ApoB, and high-sensitivity CRP ≥2 mg/L. Lp(a) should be measured at least once in adulthood.
›Coronary Artery Calcium (CAC) scoring carries a Class 1 recommendation for intermediate-risk patients when the treatment decision is uncertain (reasonable in men >40 / women >45). CAC 0 supports deferring statin therapy in those not otherwise high risk; CAC ≥100 AU (or ≥75th percentile) supports initiating therapy and an LDL-C <100 mg/dL target.

Statin Therapy and LDL-C Goals (2026)

›Statins (HMG-CoA reductase inhibitors) remain the cornerstone of lipid-lowering therapy. They reduce hepatic cholesterol synthesis, upregulate LDL receptors, and lower LDL-C by 30–55% depending on intensity. The 2026 guideline emphasizes an "earlier and lower for longer" strategy and treating to explicit LDL-C goals.
›High-intensity statins (rosuvastatin 20–40 mg, atorvastatin 40–80 mg): lower LDL-C by ≥50%. Indicated for clinical ASCVD, LDL ≥190 mg/dL, and high-risk primary prevention.
›Moderate-intensity statins (atorvastatin 10–20 mg, rosuvastatin 10 mg, simvastatin 20–40 mg, pravastatin 40–80 mg): lower LDL-C by 30–49%.
›Key 2026 indications: (1) Clinical ASCVD — high-intensity statin to LDL <70 (<55 if very high risk); add nonstatin therapy if the goal is not met. (2) LDL ≥190 mg/dL — high-intensity statin. (3) Diabetes aged 40–75 — statin recommended (Class 1) regardless of calculated risk; at minimum moderate-intensity, high-intensity preferred with additional risk factors or higher risk. (4) Primary prevention by PREVENT risk: intermediate risk → moderate- or high-intensity statin (Class 1) to LDL <100; borderline risk → moderate-intensity reasonable (Class 2a) to LDL <100; high risk → high-intensity to LDL <70 — all after a clinician–patient risk discussion.

Statin Intolerance and Alternatives

›Statin-associated muscle symptoms (SAMS): The most common reason patients stop statins. Ranges from myalgia (muscle pain without CK elevation) to myositis (elevated CK) to rare rhabdomyolysis. Evaluate: check CK, TSH, and vitamin D. Many patients labeled "statin intolerant" can tolerate a different statin at a lower dose or alternate-day dosing.
›Ezetimibe: Inhibits intestinal cholesterol absorption. Reduces LDL-C by ~18–20%. Well-tolerated. Proven to reduce cardiovascular events as add-on therapy in the IMPROVE-IT trial. Often used in statin-intolerant patients or as add-on to statin.
›PCSK9 Inhibitors (evolocumab, alirocumab): Monoclonal antibodies that block PCSK9, increasing LDL receptor recycling and dramatically reducing LDL-C (50–65%). Subcutaneous injection every 2–4 weeks. Proven mortality benefit in FOURIER and ODYSSEY OUTCOMES. Used when LDL remains above target on maximally tolerated therapy.
›Inclisiran: Small interfering RNA (siRNA) that silences hepatic PCSK9 production. Given twice yearly after initial doses. Reduces LDL-C ~50%. Approved for ASCVD and high-risk primary prevention.
›Bempedoic acid: ATP-citrate lyase inhibitor. Reduces LDL-C ~18–25%. Oral daily dosing. Does not cause muscle symptoms (prodrug activated in the liver, not muscle), and the CLEAR Outcomes trial demonstrated cardiovascular event reduction — making it a useful option in statin-intolerant patients.

Lifestyle: Mediterranean Diet and Exercise

›Diet: The Mediterranean dietary pattern — rich in olive oil, nuts, legumes, whole grains, fish, fruits, and vegetables — reduces ASCVD events and modestly lowers LDL-C. It is the most evidence-based dietary pattern for cardiovascular risk reduction.
›Dietary cholesterol: Saturated and trans fats have a greater impact on LDL-C than dietary cholesterol itself. Key messages: reduce red meat, processed meats, full-fat dairy, tropical oils (palm, coconut), and fried foods.
›Exercise: 150 minutes per week of moderate-intensity aerobic exercise (30 minutes, 5 days/week) improves lipid profiles, raises HDL-C, lowers triglycerides, and reduces ASCVD risk independent of lipid changes.
›Weight loss: Even modest weight loss (5–10%) in overweight patients can reduce LDL-C, triglycerides, and improve HDL-C.

Tie-In: The Lipid Routing Tool

›The ClearRounds Health Lipid Routing Tool provides 2026 ACC/AHA-aligned routing for lipid management, helping clinicians generate ready-to-use documentation for patient charts, referral letters, and education materials.
›For patients presenting with elevated LDL, abnormal lipid panels, statin intolerance, or complex lipid management needs, the Lipid Routing Tool can help structure the clinical note and identify appropriate next steps. It uses the PREVENT risk equations and the restored 2026 LDL-C goals (<55 very-high-risk ASCVD, <70 clinical ASCVD / high-risk primary, <100 borderline-intermediate primary prevention).

Clinical Cheat Sheet

Lipid Panel Key Values

•LDL-C: Primary treatment target
•Non-HDL-C: Total chol − HDL; includes all atherogenic particles
•HDL-C: Higher is better; <40 (men) / <50 (women) = risk factor
•Triglycerides: >150 = elevated; >500 = pancreatitis risk
•ApoB: Total atherogenic particle count; superior to LDL-C in some patients
•Lp(a): Genetically determined; measure at least once in adults

PREVENT 10-yr Risk & LDL Goals (2026)

•<3%: Low · 3–<5%: Borderline · 5–<10%: Intermediate · ≥10%: High
•Borderline/Intermediate primary prevention: LDL-C goal <100 mg/dL
•High-risk primary prevention: LDL-C goal <70 mg/dL
•Clinical ASCVD: LDL-C goal <70 mg/dL
•Very-high-risk ASCVD: LDL-C goal <55 mg/dL (non-HDL <85)
•LDL ≥190: high-intensity statin regardless of calculated risk
•DM age 40–75: statin recommended (Class 1); ≥ moderate-intensity

Statin Intensity

•High intensity: Rosuvastatin 20–40 mg, Atorvastatin 40–80 mg (LDL ↓ ≥50%)
•Moderate intensity: Rosuvastatin 10 mg, Atorvastatin 10–20 mg, Pravastatin 40–80 mg (LDL ↓ 30–49%)
•Low intensity: Simvastatin 10 mg, Pravastatin 10–20 mg (LDL ↓ <30%)

Add-On Therapy Options

•Ezetimibe: +18–20% LDL reduction; oral, well tolerated
•PCSK9 inhibitors: +50–65% LDL reduction; injectable q2–4 weeks
•Inclisiran: +50% LDL reduction; injectable twice yearly
•Bempedoic acid: +18–25% LDL reduction; oral; no muscle symptoms
•Icosapentaenoic acid (Vascepa): Reduces TG and ASCVD events in high-TG patients on statin

Nurse Assessment Checklist

Gather relevant information from patients presenting for lipid management or statin follow-up.

Medication Adherence

Is the patient taking their statin or lipid medication?
Are they taking it daily? Any missed doses?
Any side effects — muscle aches, pain, weakness?
Any muscle symptoms with a specific statin that was stopped?
Any new medications added that could interact (fibrates, certain antibiotics, antifungals)?

Symptoms to Ask About

Muscle pain or weakness (SAMS concern)
Dark or tea-colored urine (rhabdomyolysis — rare but serious)
Any unusual fatigue
Liver symptoms: nausea, abdominal pain, jaundice (rare)
Any new joint pain or difficulty with daily activities

Risk Factor Review

Smoking status — current, former, never?
Blood pressure — current readings?
Diabetes — last A1c and glucose control?
Family history of early heart disease or very high cholesterol?
Physical activity level
Dietary habits — saturated fat, processed foods, alcohol

Measurements

Blood pressure
Weight and BMI
Most recent lipid panel values and date
Most recent LFTs if on statin
CK level if muscle symptoms reported
TSH if not recently checked

Report to Provider

Medication adherence status and any side effects
Muscle symptoms and CK result if obtained
Most recent lipid panel results and trend
Vital signs and weight
Lifestyle update (diet, exercise changes)
Any new medications or supplements taken

Patient Education Handout

What is Cholesterol?

Cholesterol is a waxy substance your body makes and gets from food. Some cholesterol is needed. But too much of the "bad" kind (LDL) can build up in your arteries.
When LDL builds up, it forms plaques — like rust in a pipe. This is called atherosclerosis. Over time, plaques can block blood flow or rupture and cause a heart attack or stroke.
Controlling your cholesterol helps protect your heart and blood vessels.

Your Cholesterol Numbers

LDL cholesterol: "Bad" cholesterol — lower is better.
HDL cholesterol: "Good" cholesterol — higher is better.
Triglycerides: A type of fat in your blood — should be less than 150.
Your doctor will tell you what your target numbers are based on your overall heart health.

Why You May Need a Statin

Statins are medicines that lower LDL cholesterol. They are one of the most studied medicines in history and have been proven to reduce heart attacks and strokes.
Your doctor may recommend a statin if: your LDL is very high, you have diabetes, or you have had a heart attack, stent, or bypass surgery.
Many people worry about side effects. Most people take statins without problems. The most common side effect is mild muscle aches. If you have muscle pain, tell your doctor — do not just stop the medicine.

Heart-Healthy Eating

Eat more: fish, vegetables, fruits, nuts, olive oil, whole grains, beans and lentils.
Eat less: red meat, processed meats (hot dogs, sausage), fried foods, butter, full-fat cheese, packaged snacks, and sugary drinks.
The Mediterranean diet is a great pattern to follow for heart health.
Cooking with olive oil instead of butter or lard is a simple swap that helps.

Exercise Helps

Being active raises your good cholesterol (HDL) and lowers triglycerides.
Aim for 30 minutes of walking or other moderate activity, 5 days a week.
Even short walks add up. Start small and build up over time.

Take Your Medicines as Prescribed

Cholesterol medicines work best when taken every day.
You may not feel any different while taking them — that is normal. They are working quietly to protect your heart.
Do not stop your medicine without talking to your doctor first.
Tell your doctor if you have any side effects.

This handout is for education only and does not replace medical advice from your healthcare team.

Spanish / Communication Phrases

Interpreter Notice: These phrases are for basic communication and rapport only. Use a certified medical interpreter for diagnosis, treatment decisions, medication changes, consent, discharge instructions, and all complex clinical conversations.

Your cholesterol is high.

Su colesterol está alto.

This medicine helps protect your heart.

Este medicamento ayuda a proteger su corazón.

Are you taking your cholesterol medicine every day?

¿Está tomando su medicina para el colesterol todos los días?

Do you have any muscle pain or weakness?

¿Tiene dolor o debilidad en los músculos?

Have you noticed any dark-colored urine?

¿Ha notado que su orina está muy oscura?

Try to eat more fish, vegetables, and olive oil.

Trate de comer más pescado, verduras y aceite de oliva.

Do you smoke?

¿Fuma usted?

Try to walk 30 minutes most days.

Trate de caminar 30 minutos la mayoría de los días.

Do not stop this medicine without talking to your doctor.

No deje de tomar esta medicina sin hablar con su médico.

We need an interpreter to explain your cholesterol results and treatment plan.

Necesitamos un intérprete para explicar sus resultados de colesterol y plan de tratamiento.

Sim Patient Case

Cardiology ClinicInteractive

Patient

[EN] 55-year-old Spanish-speaking male with type 2 diabetes, hypertension, and obesity (BMI 32). No prior lipid therapy. Referred for lipid evaluation. [ES] Hombre de 55 años, hispanohablante, con diabetes tipo 2, hipertensión y obesidad (IMC 32). Sin tratamiento previo para lípidos. Referido para evaluación de lípidos.

Chief Complaint

[EN] "My doctor told me my cholesterol has been high for years. I never started medication." [ES] "Mi médico me dijo que mi colesterol ha estado alto por años. Nunca comencé medicamento."

Vitals

138/86 mmHg

78 bpm

Weight

218 lbs (BMI 32)

SpO2

98%

Temp

98.5°F

Last A1c

7.8%

Goal

[EN] Interpret the lipid panel, stratify ASCVD risk, identify appropriate statin intensity, and counsel using the lipid routing tool framework. [ES] Interprete el panel de lípidos, estratifique el riesgo de ASCVD, identifique la intensidad de estatina apropiada y oriente al paciente utilizando el marco de la herramienta de orientación de lípidos.

Knowledge Check Quiz

✉️

Stay sharp — get new modules in your inbox

New clinical topics, tools, and bedside cheat sheets for the cardiology care team. No spam, unsubscribe anytime.

Disclaimer: This content is for educational purposes only. It is not medical advice, does not replace clinical judgment, and is not a substitute for institutional protocols or certified medical interpreters. No patient health information (PHI) should be entered into this application.